Overview
Entyvio (vedolizumab) is an integrin receptor antagonist indicated for Adult Ulcerative Colitis (UC) and Adult Crohn's Disease (CD).

Coverage Guidelines

Moderately to severely active Ulcerative Colitis (UC)
Authorization may be granted for members new to AllWays Health Partners who are currently receiving treatment with Entyvio, excluding when the product is obtained as samples or via manufacturer’s patient assistance programs.

OR
Authorization may be granted for treatment of moderately to severely active UC when the following criteria are met:
1. The member has an inadequate response, intolerance or contraindication to at least one conventional therapy option (see Appendix A).

Moderately to severely active Crohn’s Disease (CD)
Authorization may be granted for members who are currently receiving treatment Entyvio, excluding when the product is obtained as samples or via manufacturer’s patient assistance programs.

OR
Authorization may be granted for treatment of moderately to severely active CD when the following criteria are met:
1. The member has an inadequate response, intolerance or contraindication to at least one conventional therapy option (see Appendix B).
**Continuation of Therapy**
Reauthorization may be granted for members, including those who are new to AllWays Health Partners, who meet ALL initial authorization criteria and achieve or maintain positive clinical response after at least 4 months of therapy with Entyvio as evidenced by low disease activity or improvement in signs and symptoms of the condition.

**Limitations**
Initial approvals and reauthorizations will be granted for 12 months.

**Appendices**

**Appendix A: Examples of Conventional Therapy Options for UC**
1. Mild to moderate disease – induction of remission:
   a. mesalamine (e.g., Asacol, Asacol HD, Lialda, Pentasa)
   b. Rectal mesalamine (e.g., Canasa, Rowasa)
   c. Alternatives: azathioprine, mercaptopurine, sulfasalazine
2. Mild to moderate disease – maintenance of remission:
   a. Oral mesalamine, rectal mesalamine
   b. Alternatives: azathioprine, mercaptopurine, sulfasalazine
3. Severe disease – induction of remission:
   a. Sulfasalazine
   b. Severe disease – maintenance of remission:
4. Azathioprine, mercaptopurine
   a. Alternative: sulfasalazine
5. Pouchitis: rectal mesalamine

**Appendix B: Examples of Conventional Therapy Options for CD**
1. Mild to moderate disease – induction of remission:
   a. Oral mesalamine (e.g., Asacol, Asacol HD, Lialda, Pentasa)
2. Mild to moderate disease – maintenance of remission:
   a. Azathioprine, mercaptopurine
   b. Alternatives: methotrexate intramuscularly (IM)
3. Moderate to severe disease – induction of remission:
   a. Methotrexate IM
4. Moderate to severe disease – maintenance of remission:
   a. Azathioprine, mercaptopurine
   b. Alternative: methotrexate IM
5. Perianal and fistulizing disease – maintenance of remission
   a. Azathioprine, mercaptopurine
   b. Alternative: methotrexate IM

**References**
1. Entyvio (vedolizumab) [prescribing information]. Deerfield, IL: Takeda Pharmaceuticals America Inc; February 2018.


Review History
02/23/15 – Reviewed
02/22/16 – Reviewed in P&T Meeting
02/27/17 – Reviewed and revised (adopted ST)
02/26/18 – Reviewed and revised
02/20/19 – Reviewed and revised in P&T Meeting
10/31/2020 – Reviewed; Updated criteria to have preferred agent for Comm/Exch strategy

Disclaimer
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.